Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · IEX Real-Time Price · USD
1.003
-0.017 (-1.71%)
Jul 22, 2024, 11:42 AM EDT - Market open
Ovid Therapeutics Employees
Ovid Therapeutics had 40 employees as of December 31, 2023. The number of employees decreased by 4 or -9.09% compared to the previous year.
Employees
40
Change (1Y)
-4
Growth (1Y)
-9.09%
Revenue / Employee
$11,838
Profits / Employee
-$1,266,919
Market Cap
71.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Gritstone bio | 231 |
Theratechnologies | 103 |
MSP Recovery | 88 |
Connect Biopharma Holdings | 81 |
Kronos Bio | 63 |
Spero Therapeutics | 46 |
enVVeno Medical | 31 |
Cognition Therapeutics | 28 |
OVID News
- 1 day ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID - GlobeNewsWire
- 14 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID - GlobeNewsWire
- 21 days ago - Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations - GlobeNewsWire
- 21 days ago - Investors who lost money on Ovid Therapeutics Inc. should contact Levi & Korsinsky about an ongoing investigation - OVID - Accesswire
- 24 days ago - OVID ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Ovid Therapeutics Inc. Investment - Accesswire
- 25 days ago - Lost Money on Ovid Therapeutics Inc.(OVID)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Accesswire
- 5 weeks ago - What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? - Benzinga
- 5 weeks ago - Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat - GlobeNewsWire